- Home
- AC vs MYGN Comparison
AC vs MYGN Comparison
Compare AC & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AC
- MYGN
- Stock Information
- Founded
- AC 1976
- MYGN 1991
- Country
- AC United States
- MYGN United States
- Employees
- AC N/A
- MYGN N/A
- Industry
- AC Investment Bankers/Brokers/Service
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- AC Finance
- MYGN Health Care
- Exchange
- AC Nasdaq
- MYGN Nasdaq
- Market Cap
- AC 809.6M
- MYGN 744.7M
- IPO Year
- AC N/A
- MYGN 1995
- Fundamental
- Price
- AC $38.06
- MYGN $4.19
- Analyst Decision
- AC
- MYGN Hold
- Analyst Count
- AC 0
- MYGN 16
- Target Price
- AC N/A
- MYGN $15.47
- AVG Volume (30 Days)
- AC 3.3K
- MYGN 3.3M
- Earning Date
- AC 05-08-2025
- MYGN 05-06-2025
- Dividend Yield
- AC 5.89%
- MYGN N/A
- EPS Growth
- AC 16.36
- MYGN N/A
- EPS
- AC 1.80
- MYGN N/A
- Revenue
- AC $12,293,000.00
- MYGN $831,300,000.00
- Revenue This Year
- AC N/A
- MYGN N/A
- Revenue Next Year
- AC N/A
- MYGN $6.42
- P/E Ratio
- AC $20.79
- MYGN N/A
- Revenue Growth
- AC N/A
- MYGN 7.38
- 52 Week Low
- AC $28.58
- MYGN $3.81
- 52 Week High
- AC $43.85
- MYGN $29.30
- Technical
- Relative Strength Index (RSI)
- AC 59.65
- MYGN 33.61
- Support Level
- AC $37.52
- MYGN $3.86
- Resistance Level
- AC $38.68
- MYGN $4.38
- Average True Range (ATR)
- AC 0.83
- MYGN 0.26
- MACD
- AC 0.11
- MYGN 0.14
- Stochastic Oscillator
- AC 74.16
- MYGN 54.29
About AC Associated Capital Group Inc.
Associated Capital Group Inc is a diversified global financial services company. It operates in the business of alternative investment management, institutional research services, and cash and other assets through subsidiaries. The activities of its subsidiaries comprise publishing daily research notes and full reports using private market value with a catalyst methodology and also products and customized solutions utilizing private market value with catalyst method of investing.
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.